Prices updated 23 June 2026, 7:40 am AEST · Data: Financial Modeling Prep
Market Cap
$512.7M
Volume
72K
P/E Ratio
14.96
EPS
$0.2082
Dividend Yield
0.40%
52-Week High
$14.00
52-Week Low
$8.35
Beta
0.606
Clinuvel Pharmaceuticals (ASX: CUV) is an Australian-listed company in the Healthcare sector with a market capitalisation of $512.7M and the 456th-largest security on the ASX by market capitalisation. The CUV share price is $10.17, down 1.26% today and up 3.48% over the past 12 months. Shares have traded between $8.35 and $14.00 over the past 52 weeks. CUV trades on a price-to-earnings ratio of 14.96, above the Healthcare sector median of 14.96, and pays a trailing dividend yield of 0.40%. In its most recent reported period (ending 31 Dec 2025), Clinuvel Pharmaceuticals reported revenue of $36.9M and a net profit of $10.4M (28.3% margin).
Charts
$10.14
24H Range
$9.97
$10.30
52-Week Range
$8.35
$14.00
About Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of treatments for patients battling genetic, metabolic, and life-threatening conditions. Its reach extends across Australia, Europe, the United States, Switzerland, and other global markets. The company's flagship drug, SCENESSE, serves as a systemic photoprotective treatment intended to prevent phototoxicity in adult patients diagnosed with erythropoietic protoporphyria (EPP). Clinuvel's development pipeline includes CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which promotes prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Additionally, Clinuvel Pharmaceuticals has partnered with HK Winhealth Pharma Group Co. Limited for a named patient program in the People's Republic of China, enabling the treatment of EPP patients with SCENESSE. Founded in 1987, the company's corporate headquarters are situated in Melbourne, Australia.
What is the Clinuvel Pharmaceuticals (ASX: CUV) share price?
The CUV share price is $10.17, down 1.26% for the day, based on the latest available ASX market data.
What is Clinuvel Pharmaceuticals's market capitalisation?
Clinuvel Pharmaceuticals has a market capitalisation of $512.7M, making it the 456th-largest security listed on the ASX.
Does Clinuvel Pharmaceuticals pay a dividend?
Yes. CUV has a trailing dividend yield of 0.40%.
What is CUV's P/E ratio?
Clinuvel Pharmaceuticals trades on a trailing price-to-earnings (P/E) ratio of 14.96, based on its current share price and most recent reported earnings.
Is Clinuvel Pharmaceuticals profitable?
Yes. In its most recent reported period (ending 31 Dec 2025), CUV reported revenue of $36.9M and a net profit of $10.4M.
How many CUV shares are on issue?
Clinuvel Pharmaceuticals has approximately 50,410,800 shares on issue, based on its market capitalisation of $512.7M and current share price.
What sector is Clinuvel Pharmaceuticals in?
Clinuvel Pharmaceuticals is classified in the Healthcare sector, within the Biotechnology industry on the ASX.
When did Clinuvel Pharmaceuticals list on the ASX?
Clinuvel Pharmaceuticals listed on the Australian Securities Exchange on 11 Feb 2001.
CUV is held by 2 ASX-listed funds tracked on this site. The largest allocation is in iShares S&P/ASX Small Ordinaries ETF (ASX: ISO) at 0.16% of its portfolio.
